# Cost-Effectiveness Analysis of Pitavastatin in Dyslipidemia: Vietnam Case

**Authors:** Nam Xuan Vo, Hanh Thi My Nguyen, Nhat Manh Phan, Huong Lai Pham, Tan Trong Bui, Tien Thuy Bui

PMC · DOI: 10.3390/healthcare13192494 · Healthcare · 2025-10-01

## TL;DR

The study evaluates if pitavastatin is a cost-effective treatment for dyslipidemia in Vietnam compared to other statins.

## Contribution

The novelty lies in assessing pitavastatin's cost-effectiveness in Vietnam's healthcare context.

## Key findings

- Pitavastatin was found to be cost-effective compared to atorvastatin.
- Rosuvastatin dominated pitavastatin in terms of effectiveness and cost.
- Drug cost was the most influential factor in cost-effectiveness outcomes.

## Abstract

Background/Objectives: Dyslipidemia is becoming a significant economic healthcare burden in low- to middle-income countries (LMICs) due to its role in heightening cardiovascular-related mortality. Statins are the first-line treatment for reducing LDL-C levels, thereby minimizing direct costs associated with cardiovascular disease management, with pitavastatin being of the newest generation of statins. This research work conducted a cost-utility analysis of pitavastatin to determine the economic benefit in Vietnam. Methods: A decision tree model was developed to compare the rate of LDL-C controlled patients over a lifetime horizon among patients treated with pitavastatin, atorvastatin, and rosuvastatin. The primary outcome was the incremental cost-effectiveness ratio (ICER), measured from the healthcare system perspective. Effectiveness was evaluated in terms of quality-adjusted life years (QALYs), using an annual discount rate of 3%. A one-way sensitivity analysis was performed to identify the key input parameters that most influenced the ICER outcomes. Results: Pitavastatin was cost-effective compared to atorvastatin but was dominated by rosuvastatin. Although pitavastatin gained fewer QALYs than atorvastatin, the ICER was 195,403,312 VND/QALY, well below Vietnam’s 2024 willingness-to-pay. Drug cost had the most significant impact on ICERs. Conclusions: Pitavastatin represents an economical short-term alternative to atorvastatin, particularly in resource-constrained settings.

## Linked entities

- **Chemicals:** pitavastatin (PubChem CID 5282452), atorvastatin (PubChem CID 60823), rosuvastatin (PubChem CID 446157)
- **Diseases:** dyslipidemia (MONDO:0002525), cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Diseases:** Dyslipidemia (MESH:D050171), cardiovascular disease (MESH:D002318)
- **Chemicals:** LDL-C (-), Pitavastatin (MESH:C108475), atorvastatin (MESH:D000069059), rosuvastatin (MESH:D000068718)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12524106/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12524106/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12524106/full.md

---
Source: https://tomesphere.com/paper/PMC12524106